Company intelligence / Profile preview
Minghui Pharmaceutical, Inc.
Shanghai and Hangzhou, Chinaminghuipharma.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Minghui Pharmaceutical has multiple programs in clinical development, with promising results from several trials. Their tofacitinib etocomil is in Phase 3 for mild atopic dermatitis. MHB088C (B7-H3 ADC) has shown promising efficacy and safety in over 150 patients with various tumor types. MHB039A (PD-1 x VEGF bispecific antibody) demonstrated favorable safety and promising anti-tumor activity in heavily pretreated patients. MHB018A (IGF-1R antibody) showed positive topline results in thyroid eye disease patients.
- Therapeutic areas
- OncologyEndocrinologyDermatology
- Modalities
- Small molecule drugsAntibody drug conjugates (ADCs)Bispecific antibodiesMonoclonal antibodiesFusion proteins
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on Minghui Pharmaceutical, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minghui Pharmaceutical, Inc..